Why is a Normal Ejection Fraction a Warning in HCM?
At a Glance
In Hypertrophic Cardiomyopathy (HCM), a "normal" ejection fraction (EF) of 50-55% is a warning sign. Because an HCM heart typically squeezes at 65-75%, a drop to normal levels means the heart muscle is weakening, requiring a change in treatment from relaxing the heart to supporting its function.
In this answer
3 sections
If you have Hypertrophic Cardiomyopathy (HCM), an ejection fraction (EF) of 50% to 55% is a warning sign, even though it is considered a perfectly healthy number for someone without the condition. In a typical heart, a normal EF is between 55% and 70%. However, an HCM heart is usually hypercontractile (overactive)—meaning it squeezes much harder than a normal heart, often pumping out 65% to 75% of its blood with each beat [1][2]. For someone with HCM, a drop from these high numbers down into the 50–55% range means the previously thickened heart muscle is losing its abnormal strength and is beginning to weaken.
The Shift to Systolic Dysfunction
Why does this drop in squeezing power happen? Over time, the thickened, overworked heart muscle in HCM can undergo structural changes. The healthy muscle fibers can become replaced by scar tissue, a process known as myocardial fibrosis [3][4]. As this scar tissue builds up, the heart wall may actually thin out and lose its ability to pump forcefully [5][6].
When an HCM patient’s ejection fraction drops below 50%, cardiologists refer to this as the “burned-out” or “end-stage” phase of the disease [7][5][8]. It is critical to know that “end-stage” does not mean terminal or the end of your life. Instead, it is a medical term meaning the hypertrophic (thickened) phase of the disease has ended, and your heart has shifted into a phase of systolic heart failure (a weakened squeeze). Because an EF of 50-55% is right on the edge of this threshold, doctors treat it as a major red flag that the heart is transitioning toward this new phase, which remains highly treatable.
Symptoms to Watch For
As your ejection fraction drops, you may notice new or worsening physical symptoms. Because your heart is not pumping as efficiently, you should alert your doctor if you experience:
- Increased fatigue or exhaustion during normal activities
- New or worsening shortness of breath, especially when lying down
- Swelling (fluid retention) in your legs, ankles, or abdomen
Why a Dropping EF Changes Your Care
A declining ejection fraction requires a complete shift in how your medical team manages your condition, changing focus from calming an overactive heart to supporting a weakened one [9][10][11].
- Medication Adjustments: Standard HCM medications—such as beta-blockers, calcium channel blockers, or newer targeted drugs like mavacamten (Camzyos)—are designed to relax the heart and reduce its powerful squeeze. If your heart is naturally losing its pumping power, these medications could drop your EF dangerously low. In fact, strict safety protocols require doctors to stop targeted myosin inhibitors if your EF drops below 50% [12][13].
- New Treatment Strategies: To support your heart’s new phase, your doctor will likely introduce medications used for standard heart failure, such as ACE inhibitors, ARBs, SGLT2 inhibitors, or diuretics to help manage fluid buildup. In some cases, specialized pacemakers (CRT) or implantable defibrillators (ICDs) may be discussed.
- Advanced Imaging: Your doctor will likely order a cardiac MRI, which is the best tool to look for scar tissue (late gadolinium enhancement) and accurately measure how much the structure of your heart muscle has changed [6][14].
Understanding your “baseline” ejection fraction—what is normal for your heart—is crucial. A drop to 55% requires close monitoring and proactive adjustments to protect your heart’s remaining function.
Common questions in this guide
Why is an ejection fraction of 50% considered a warning sign in HCM?
What does end-stage or burned-out HCM mean?
What symptoms should I watch for if my ejection fraction is dropping?
How does a dropping ejection fraction change my HCM treatment?
Will I need new imaging tests if my ejection fraction drops?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What was my baseline Ejection Fraction when I was first diagnosed, and how does my current EF compare?
- 2.Given my recent EF, do we need to taper or stop any of my current medications, such as beta-blockers or myosin inhibitors?
- 3.Should we schedule a Cardiac MRI to check for myocardial fibrosis or changes in the thickness of my heart wall?
- 4.Are there any standard heart failure medications or new treatment strategies we should consider to support my heart's pumping function?
- 5.How frequently should we be monitoring my Ejection Fraction moving forward?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
Impact of the Myosin Modulator Mavacamten on Force Generation and Cross-Bridge Behavior in a Murine Model of Hypercontractility.
Mamidi R, Li J, Doh CY, et al.
Journal of the American Heart Association 2018; (7(17)):e009627 doi:10.1161/JAHA.118.009627.
PMID: 30371160 - 2
Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.
Młynarska E, Radzioch E, Dąbek B, et al.
Biomedicines 2024; (12(12)) doi:10.3390/biomedicines12122675.
PMID: 39767581 - 3
The Impact of Ischemia Assessed by Magnetic Resonance on Functional, Arrhythmic, and Imaging Features of Hypertrophic Cardiomyopathy.
Aguiar Rosa S, Thomas B, Fiarresga A, et al.
Frontiers in cardiovascular medicine 2021; (8()):761860 doi:10.3389/fcvm.2021.761860.
PMID: 34977179 - 4
Altered coronary artery function, arteriogenesis and endothelial YAP signaling in postnatal hypertrophic cardiomyopathy.
Langa P, Marszalek RJ, Warren CM, et al.
Frontiers in physiology 2023; (14()):1136852 doi:10.3389/fphys.2023.1136852.
PMID: 37064918 - 5
Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis.
Wasserstrum Y, Larrañaga-Moreira JM, Martinez-Veira C, et al.
ESC heart failure 2022; (9(4)):2301-2312 doi:10.1002/ehf2.13914.
PMID: 35488723 - 6
"Burned-Out" Hypertrophic Cardiomyopathy: Overlap on Cardiac MRI With Other Nonischemic Cardiomyopathies.
Wunderly K, Ajluni S, O'Hayer P, Attili A
JACC. Case reports 2026; (31(11)):106940 doi:10.1016/j.jaccas.2026.106940.
PMID: 41697182 - 7
Elevation of high-sensitivity cardiac troponin T and left ventricular remodelling in hypertrophic cardiomyopathy.
Kubo T, Ochi Y, Baba Y, et al.
ESC heart failure 2020; (7(6)):3593-3600 doi:10.1002/ehf2.12852.
PMID: 33047518 - 8
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy.
Pasqualucci D, Fornaro A, Castelli G, et al.
Circulation. Heart failure 2015; (8(6)):1014-21 doi:10.1161/CIRCHEARTFAILURE.114.001843.
PMID: 26446673 - 9
Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: Relationship to outcomes.
Desai MY, Smedira NG, Bhonsale A, et al.
The Journal of thoracic and cardiovascular surgery 2015; (150(4)):928-35.e1.
PMID: 26318357 - 10
"Burnt out" dilated hypertrophic cardiomyopathy causing acute LVAD thrombosis.
Sivathasan C, Tan TE, Sim D, Kerk KL
Clinical case reports 2015; (3(6)):376-8 doi:10.1002/ccr3.237.
PMID: 26185632 - 11
Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure.
Nguyen A, Schaff HV, Nishimura RA, et al.
The Journal of thoracic and cardiovascular surgery 2020; (159(1)):145-152 doi:10.1016/j.jtcvs.2019.03.088.
PMID: 31053431 - 12
Effect of Cardiac Myosin Inhibitors on Echocardiographic Features of Cardiac Structure and Function in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.
Lu Y, Zhu Y, Tian Z
Reviews in cardiovascular medicine 2026; (27(1)):45043 doi:10.31083/RCM45043.
PMID: 41659081 - 13
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.
Owens AT, Desai M, Wheeler MT, et al.
Journal of the American Heart Association 2024; (13(17)):e033767 doi:10.1161/JAHA.124.033767.
PMID: 39206723 - 14
Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts.
Galati G, Leone O, Pasquale F, et al.
Circulation. Heart failure 2016; (9(9)).
PMID: 27618852
This page explains ejection fraction changes in hypertrophic cardiomyopathy for educational purposes only. Always consult your cardiologist to interpret your specific echocardiogram and MRI results.
Get notified when new evidence is published on Hypertrophic Cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.